Valuation : Alcon

Market Cap 3.4TCr 2.93TCr 2.75TCr 2.51TCr 4.7TCr 3,21900Cr 4.72TCr 33TCr 13TCr 1,64900Cr 13TCr 13TCr 5,25100Cr P/E 2026 *
39.6x
P/E 2027 * 25.1x
Enterprise Value 3.66TCr 3.15TCr 2.96TCr 2.7TCr 5.05TCr 3,46000Cr 5.07TCr 35TCr 14TCr 1,77200Cr 14TCr 13TCr 5,64400Cr EV / Sales 2026 *
3.3x
EV / Sales 2027 * 3.01x
Free-Float
97.34%
Yield 2026 *
0.53%
Yield 2027 * 0.59%
Manager TitleAgeSince
Chief Executive Officer 60 01/07/2018
Director of Finance/CFO 58 08/04/2019
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 01/07/2018
Director/Board Member 63 01/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+19.99%0.00% - - 3.4TCr
+0.81%-6.14%-42.84%-13.61% 7.94TCr
-0.37%-2.64%-10.19%-22.88% 3.4TCr
-1.49%-0.71%+2.20%-21.31% 1.36TCr
+1.29%+4.92% - - 1.26TCr
+2.57%+3.00%-1.52%+585.18% 264.4Cr
-0.54%-0.99%-38.83%-57.70% 146.46Cr
-0.17%+10.88% - - 97Cr
-1.43%-5.01%+17.49%+2.43% 92Cr
-1.00%-0.97%-35.94%-19.99% 89Cr
Average -0.01%-1.34%-15.66%+64.59% 1.63TCr
Weighted average by Cap. +0.34%-4.57%-28.55%-5.28%

Financials

2026 *2027 *
Net sales 1.11TCr 953.66Cr 896.95Cr 818.79Cr 1.53TCr 1,04900Cr 1.54TCr 11TCr 4.11TCr 54TCr 4.16TCr 4.07TCr 1,71100Cr 1.18TCr 1.01TCr 952.32Cr 869.33Cr 1.63TCr 1,11300Cr 1.63TCr 11TCr 4.36TCr 57TCr 4.42TCr 4.32TCr 1,81600Cr
Net income 76Cr 66Cr 62Cr 56Cr 105.53Cr 7.23TCr 105.87Cr 732.91Cr 283.3Cr 3.7TCr 286.99Cr 280.72Cr 12TCr 125.89Cr 108.27Cr 101.83Cr 93Cr 173.85Cr 12TCr 174.41Cr 1.21TCr 466.69Cr 6.1TCr 472.77Cr 462.44Cr 19TCr
Net Debt 254.48Cr 218.85Cr 205.84Cr 187.9Cr 351.42Cr 24TCr 352.56Cr 2.44TCr 943.39Cr 12TCr 955.68Cr 934.79Cr 39TCr 144.99Cr 124.7Cr 117.28Cr 107.06Cr 200.23Cr 14TCr 200.88Cr 1.39TCr 537.51Cr 7.02TCr 544.51Cr 532.61Cr 22TCr
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!